Researchers found that a new type of therapy using engineered immune cells, called Regenerative Macrophage Therapy (RMT), shows promise for treating severe liver disease. This therapy, developed by Resolution Therapeutics, uses modified immune cells to improve patient outcomes and reduce inflammation in the liver. The latest data from a four-year follow-up study at the University of Edinburgh indicates that 70% of patients receiving this therapy were able to live without needing a liver transplant, compared to only 40% of those receiving standard care.

This finding is significant for anyone concerned about liver health or aging, especially those at risk for liver-related complications. The therapy targets patients with end-stage liver disease, a condition that can lead to serious health issues, including liver failure. By enhancing the body’s own immune response, this treatment could potentially help many people maintain better liver function and overall health as they age.

The research is still in its early stages, with the MATCH trial being the first to test this type of therapy in humans. While the results are encouraging, they come from a small group of patients and more extensive studies are needed to confirm the benefits and safety of this treatment. Interim results from a larger trial, the EMERALD study, are expected later this year, which will provide further insights into the effectiveness of this engineered therapy.

If you’re interested in supporting liver health, consider maintaining a balanced diet, staying hydrated, and avoiding excessive alcohol consumption. While this therapy is not yet widely available, staying informed about advances in liver treatments can empower you to make healthier choices.

Source: globenewswire.com